Research programme: epithelial sodium channel antagonists - DiscoveryBioMed
Latest Information Update: 07 Jul 2022
Price :
$50 *
At a glance
- Originator DiscoveryBioMed
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis; Hypertension
Most Recent Events
- 05 Jul 2022 DiscoveryBioMed has been acquired by Eurofins Discovery
- 04 Nov 2017 No recent reports of development identified for research development in Cystic-fibrosis in USA
- 04 Nov 2017 No recent reports of development identified for research development in Hypertension in USA